STALLERGENES enters the Netherlands through a joint-venture agreement

Antony,France (Feb. 13, 2007) 'Stallergenes SA today announced that it has set up a joint-venture in the Netherlands in partnership with the Dutch company Sanmed B.V.

The agreement represents an important step forward in Stallergenes'strategy to be present in the Dutch market, the fifth largest desensitization market in Europe. In 2006, the Dutch market has reached an estimated value of 37 million euros and is dominated by sublingual treatments, which have experienced a growth of 18%.

Under the terms of the agreement, 51% of the shares of the newly established entity Stallergenes B.V will belong to Stallergenes S.A. The objective of Stallergenes B.V is to distribute and promote the existing range of Stallergenes' products on the Dutch market, and then launch the sublingual desensitization tablets once approved through the Mutual Recognition Procedure.

"We are very pleased to enter this agreement with Sanmed B.V.. The Company has a demonstrated track record in launching and promoting licensed-in products on the Dutch market" said Albert Saporta, Chairman and CEO of Stallergenes. "We are confident that their market knowledge and their local infrastructure, combined with our long-standing expertise in desensitization should help develop the very dynamic Dutch market."